PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells  by Calvo, M.N. et al.
FEBS Letters 580 (2006) 3308–3314PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay
and inhibits anchorage-independent growth in HeLa cells
M.N. Calvoa, R. Bartronsa,*, E. Castan˜oc, J.C. Peralesb, A. Navarro-Sabate´a, A. Manzanoa
a Unitat de Bioquı´mica, Departament de Cie`ncies Fisiolo`giques II, Campus de Cie`ncies de la Salut, IDIBELL-Universitat de Barcelona,
Feixa Llarga s/n E-08907 L’Hospitalet, Barcelona, Spain
b Unitat de Biofı´sica, Departament de Cie`ncies Fisiolo`giques II, Campus de Cie`ncies de la Salut, IDIBELL-Universitat de Barcelona,
Feixa Llarga s/n E-08907 L’Hospitalet, Barcelona, Spain
c Serveis Cientı´ﬁco-Te`cnics, Campus de Cie`ncies de la Salut, IDIBELL-Universitat de Barcelona, Feixa Llarga s/n E-08907 L’Hospitalet,
Barcelona, Spain
Received 30 March 2006; revised 27 April 2006; accepted 28 April 2006
Available online 8 May 2006
Edited by Judit Ova´diAbstract The high rate of glycolysis despite the presence of
oxygen in tumor cells (Warburg eﬀect) suggests an important
role for this process in cell division. The glycolytic rate is depen-
dent on the cellular concentration of fructose 2,6-bisphosphate
(Fru-2,6-P2), which, in turn, is controlled by the bifunctional
enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
(PFK-2). The ubiquitous PFK-2 isoenzyme (uPFK-2, alterna-
tively named UBI2K5 or ACG) coded by the pfkfb3 gene is
induced by diﬀerent stimuli (serum, progesterone, insulin, hypox-
ia, etc.) and has the highest kinase/phosphatase activity ratio
amongst all PFK-2 isoenzymes discovered to date, which is con-
sistent with its role as a powerful activator of glycolysis. uPFK-2
is expressed in brain, placenta, transformed cells and proliferat-
ing cells. In the present work, we analyze the impact of small
interfering RNA (siRNA)-induced silencing of uPFK-2 on the
inhibition of cell proliferation. HeLa cells treated with uPFK-2
siRNA showed a decrease in uPFK-2 RNA levels measured at
24 h. uPFK-2 protein levels were severely depleted at 48–72 h
when compared with cells treated with an unrelated siRNA, cor-
relating with decreased glycolytic activity, Fru-2,6-P2, lactate
and ATP concentrations. These metabolic changes led to reduced
viability, cell-cycle delay and an increase in the population of
apoptotic cells. Moreover, uPFK-2 suppression inhibited anchor-
age-independent growth. The results obtained highlight the
importance of uPFK-2 on the regulation of glycolysis, on cell
viability and proliferation and also on anchorage-independent
growth. These data underscore the potential for uPFK-2 as an
eﬀective tumor therapeutic target.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cancer cells maintain an abnormally high glycolytic rate
even in the presence of oxygen, a phenomenon ﬁrst described
by Otto Warburg and subsequently known as the Warburg ef-
fect [1], and observed in a wide spectrum of human tumors.
Although the underlying mechanisms responsible for this eﬀect
are rather complex and have not been deﬁnitively elucidated,*Corresponding author. Fax: +34 93 4024268.
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causes [2]. In physiological conditions, the cellular energy
metabolism is based, preferentially, on oxidative phosphoryla-
tion, which is more eﬃcient than glycolysis. In cancer cells, the
factors responsible for the Warburg eﬀect compromise the
ability of cells to generate ATP via mitochondrial respiration,
which triggers alternative metabolic pathways by, among other
processes, preferential overexpression of glycolysis enzymes
[3]. The high glycolytic rate allows the cells to balance their en-
ergy demands and supply the anabolic precursors for de novo
nucleotide synthesis [4]. This strategy is considered to provide
a growth advantage for the tumor cell, although it renders cells
highly dependent on glycolysis for survival [5]. Another feature
of malignant transformation is the ability of cells to grow in an
anchorage-independent manner [6].
Phosphofructokinase-1 (PFK-1), a rate-limiting enzyme of
glycolysis, is allosterically activated by Fru-2,6-P2, a metabo-
lite that can override the inhibitory eﬀect of ATP on PFK-1
[7]. Fructose 2,6-bisphosphate (Fru-2,6-P2) levels are increased
in proliferative and transformed cells [4,8–10] as well as in var-
ious tumors [11]. Production and degradation of Fru-2,6-P2
depend on several PFK-2 isoenzymes coded by four genes
(pfkfb1–4) (reviewed in [12,13]). The expression of these genes
is dependent on tissue and on development stage [14]. Impor-
tantly, tissue-speciﬁc isoenzymes are not totally exclusive and
several tissues express more than one isoenzyme. This pattern
of expression suggests that each isoenzyme plays a key role un-
der diﬀerent physiological conditions or in response to diﬀer-
ent hormonal stimuli.
Pfkfb3 gene codes for ubiquitous (uPFK-2) –the isoenzyme
with the highest kinase/bisphosphatase ratio [15]- and induc-
ible (iPFK-2) PFK-2 isoenzymes [16]. The occurrence of six
alternative splicing variants of human pfkfb3 gene, two of
which are the ubiquitous PFK-2 (alternatively named UBI2K5
or ACG) and the inducible PFK-2 (UBI2K4 or ACDG), has
been described [17]. There is evidence for upregulation of
pfkfb3 expression in response to hypoxia and other stimuli
[4,12,13,18]. It has been suggested that tumor cells upregulate
glycolytic enzymes by increasing protein synthesis and by
switching to the preferential expression of the isoenzymes with
a higher tendency to catalyze a reaction in the direction that is
more favorable for the tumor [19], which has been demon-
strated for PFK-2 [9,18]. Moreover, pfkfb3 gene is distin-
guished by the presence of multiple copies of the AUUUA
sequence in the 3 0 UTR of its mRNA. The AUUUA motif isblished by Elsevier B.V. All rights reserved.
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and confers instability and enhanced translational activity [4].
Herein, we report the use of RNA interference to knock-
down uPFK-2. Our results corroborate its putative role in
sustaining the high glycolytic ﬂux in proliferative cells [20]
and provide evidence of its involvement in cell viability preser-
vation, cell-cycle progression and anchorage-independent
growth.2. Materials and methods
2.1. Cell culture
HeLa, HEK-293, MCF7 and T47D cell lines obtained from the
American Type Culture Collection (Manassas, VA) were cultured in
a 10% CO2 humidiﬁed atmosphere at 37 C as exponentially growing
monolayers in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with
glutamax (Invitrogen), supplemented with 10% fetal calf serum (Invit-
rogen) and penicillin/streptomycin (100 U/ml and 100 lg/ml).
2.2. siRNA design and transfection
Small interfering RNAs (siRNAs) were designed according to criteria
outlined elsewhere [21]. Speciﬁcity was checked by using BLAST and
comparing positions in the alignment of the diﬀerent human PFK-2 se-
quences. siRNA against uPFK-2 (u-siRNA) targets a sequence in the
ubiquitous PFK-2 mRNA located between nucleotide positions 1501
and 1520 relative to the ﬁrst nucleotide of the start codon of pfkfb3 gene
[AF109735] (AGCUGCCUGGACAAAACAUG) that is found trun-
cated in the mRNA of iPFK-2 (UBI2K4 or ACDG). Also, an siRNA
against a common region of all mRNAs generated from pfkfb3 (co-
siRNA) and, as a negative control, two non-functional siRNAs with
no human target (c() siRNA) were used. All siRNAs were synthesized
by Dharmacon Research, Inc. Transfections were performed with
Oligofectamine (Invitrogen) as speciﬁed by the manufacturer.
2.3. RNA extraction and real-time PCR
Total RNA was extracted using Ultraspect (Biotecx Laboratories,
Inc), according to the manufacturer’s protocol. The RNA was reverse
transcribed using Ready-To-GoTM You-Prime First-Strand Beads
(Amersham Biosciences) and oligo(dT)1218 primer (Amersham-
Pharmacia Biotech). pfkfb3 was speciﬁcally ampliﬁed by using the
probe/primer set for human pfkfb3 (Hs0019079_m1) (Applied Biosys-
tems). TBP (housekeeping control gene, TATA-box binding protein)
(Hs00427620_m1) was used for normalization. PCR data were cap-
tured using an ABIPRISM 7700 Sequence Detection System.
2.4. Protein extraction and Western blot analysis
Equal amounts of total protein extracts, prepared from the same
number of untransfected cells and cells transfected with siRNA, were
analyzed in 10% (w/v) SDS–PAGE. Western blot was performed
according to [22] using the rabbit polyclonal sera against uPFK-2
(1:500) [23], commercial antibodies against liver (Santa Cruz) and
heart (Abgent) PFK-2, and a polyclonal speciﬁc antibody against testis
PFK-2 [24] and, for protein loading control, a mouse monoclonal anti-
body against a-tubulin (1:1000) (Sigma). Peroxidase-conjugated sec-
ondary antibodies against mouse and rabbit (Amersham Bioscience)
were used at 1:5000. Immunostaining was carried out using the ECL
technique (Amersham–Pharmacia Biotech).
2.5. Metabolite determination
Fru-2,6-P2 was determined following the method described by Van
Schaftingen et al. [25]. Lactate and ATP were measured spectrophoto-
metrically in neutralized perchloric extracts by using standard enzy-
matic methods [26]. Protein concentration was determined by the
Bradford-based Bio-Rad assay.
2.6. Viability and proliferation assays
2.6.1. Cell number assay. Cell number was determined by crystal
violet staining as previously described [27]. The absorbance read at
550 nm was proportional to the number of cells that remained attached
to the plate.2.6.2. Staining by annexin V and propidium iodide. The appearance
of apoptotic or necrotic cells was determined by the annexin V binding
assay [28]. The aﬃnity of annexin V for phosphatidylserine residues al-
lows the percentage of cells undergoing apoptosis to be quantiﬁed by
ﬂow cytometry. Apoptotic and necrotic cells were distinguished on
the basis of double-labeling for annexin V-FITC (Bender) and propi-
dium iodide (PI), a membrane-impermeable DNA stain. Floating
and freshly trypsinized cells were pooled, washed twice in binding buf-
fer and processed following manufacturer’s instructions. Cells ﬂuores-
cence was analyzed by ﬂow cytometry (FACSCalibur, Becton
Dickinson, Mountain View, CA) using the Cell Quest Pro software.
2.6.3. Cell-cycle analysis by ﬂow cytometry. After trypsinization,
cells were washed in PBS containing 1% calf serum and ﬁxed by adding
cold ethanol to a ﬁnal concentration of 80%. After washing and resus-
pending ﬁxed cells in 0.5 ml of PBS containing 1% calf serum, the
DNA was stained by adding 200 lg/ml of propidium iodide and
10 mg/ml of DNAse-free RNAse A. Stained cells were analyzed using
FACSCalibur system (Becton Dickinson, MountainView, CA). The
percentage of cells in each phase of the cell cycle was determined using
the Modﬁt 5.2 computer program.
2.7. Anchorage-independent growth assay
HeLa cells treated with the corresponding siRNA (u-siRNA, co-siR-
NA and two diﬀerent non-functional c()1 and 2 siRNAs as negative
controls) or with Oligofectamine alone (control condition) were seeded
24 h after transfection in triplicate in 12-well plates. For this purpose,
5 · 103 cells/well were plated in 0.3% agarose DMEM medium onto a
semisolid 0.6% agarose DMEM layer. Complete medium containing
2.5 nM paclitaxel was added to positive control wells and maintained
for 24 h. The remaining wells were supplied with complete medium
alone or containing 1 nM siRNA (siRNA redosing) [29]. Medium
was changed every two days. After 10 days, colonies of 50 cells or more
were counted from at least four randomly selected ﬁelds per triplicate
well.
2.8. Data analysis
Results are shown as the mean ± S.E.M. of the values obtained from
the indicated number of experiments. Diﬀerences between groups were
analyzed by Student’s t test. Signiﬁcant diﬀerences at P < 0.05,
P < 0.01, and P < 0.001 vs. negative control are indicated by *, **,
and ***, respectively.3. Results and discussion
The aim of our work was to investigate the biological conse-
quences of the speciﬁc knock-down of uPFK-2 (UBI2K5 or
ACG). Firstly, we determined the presence of diﬀerent isoen-
zymes of PFK-2 in several cell lines (HEK-293, HeLa, T47D
and MCF7) by Western blot (Fig. 1A). HeLa cells expressed
all the isoforms analyzed (Fig. 1A and E). Initial validation
using u-siRNA and co-siRNA at 100 nM demonstrated high
levels of silencing (60–90%) in most of the cell lines assayed
(data not shown). We focused on HeLa cells due to their high
growth rate and transfection eﬃciency. We next tested the
silencing dose–response and time-course by real-time PCR
and Western blot, respectively. Total RNA was extracted from
HeLa cells 24 h after transfection and analyzed with speciﬁc
probe/primers for pfkfb3 and for TATA-box binding protein
housekeeping control gene. There was a signiﬁcant decrease
in mRNA levels from 10 to 100 nM siRNA (Fig. 1B). In light
of these data, we chose 100 nM as the optimal working con-
centration, also in agreement with manufacturer’s instructions.
Western blots from cells transfected at 100 nM siRNA re-
vealed decreased levels of uPFK-2 48 h after transfection,
which were lowest at 72 h (Fig. 1C). In order to monitor the
possible non-speciﬁc inhibition of translation due to an inter-
feron-mediated response [30], we measured the activation of
the small subunit of eucaryotic initiation factor 2-a (eIF2-a).
Fig. 1. Western blot and real-time PCR analysis. (A) PFK-2 isoenzymes (liver PFK-2, LPFK-2; ubiquitous PFK-2, uPFK-2 (UBI2K5 or ACG), and
testis PFK-2, tPFK-2) expression in diﬀerent cell lines (HEK-293, HeLa, T47D and MCF7). (B) pfkfb3 silencing measured by real-time PCR 24 h
post-transfection. Results are normalized to the housekeeping control gene TBP and expressed as fold change versus control. (C) uPFK-2 silencing
measured by Western blot at various times after transfection (100 nM siRNA). Bars diagram represents average of at least three independent
experiments. Diﬀerences P < 0.001 (***) were considered signiﬁcant. (D) uPFK-2 silencing dose–response analyzed by Western blot. Non-speciﬁc
inhibition of translation was checked by analyzing P-eIF2a/eIF2a ratio. Quantiﬁcation based on densitometric analysis of the Western blot above is
represented by the bars diagram. (E) PFK-2 isoenzymes expression (ubiquitous PFK-2, uPFK-2; liver PFK-2, LPFK-2; heart PFK-2, hPFK-2 and
testis PFK-2, tPFK-2) in HeLa cells treated with siRNA measured by Western blot. a-tubulin (aTub) is shown as a protein loading control. In all
cases, unless diﬀerently stated, a representative of at least three experiments is shown. Abbreviations: c, Oligofectamine control; c(), negative
control siRNA; ub, siRNA against uPFK-2; u-siRNA; co, siRNA against all pfkfb3 mRNAs.
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vated protein kinase (PKR) in the presence of double-stranded
RNA longer than 30 bp. The dose–response (Fig. 1D) showed
a decrease in the levels of uPFK-2 from 30 to 120 nM without
alterations in the P-eIF2a/eIF2a ratio. Besides, it has been re-
ported that chemically-synthesized siRNAs do not usually
activate the antiviral response in mammal cells [31,32]. Finally,
we examined whether the silencing of uPFK-2 would upregu-
late the expression of other PFK-2 isoenzymes and no signiﬁ-
cant diﬀerences were found (Fig. 1E).
Silencing uPFK-2 is expected to decrease Fru-2,6-P2 levels.
The response of Fru-2,6-P2 concentrations to extracellular
and metabolic signals or to the inhibition of its producing en-zyme depends on the PFK-2 isoenzymes present in the cell,
whose distinctive kinase/bisphosphatase ratio and diﬀerent
regulatory N- and C-terminal domains are adapted to the
function of diﬀerent organs [12,13]. A signiﬁcant 20–30% de-
crease in Fru-2,6-P2 levels was observed 72 h after transfection
(Fig. 2). To establish whether the changes in Fru-2,6-P2 levels
had an immediate eﬀect on the cellular glycolytic activity, we
measured lactate levels from cell culture medium and cellular
ATP content. uPFK-2 knock-down cells showed a decrease
of 23% and 20% in lactate and ATP levels, respectively
(Fig. 2). Pe´rez et al. [33] showed that overexpression of a trun-
cated form of PFK-2 carrying only the bisphosphatase domain
in Mv1Lu cells induced a decrease in Fru-2,6-P2 levels that cor-
Fig. 2. Eﬀect of uPFK-2 silencing on Fru-2,6-P2, lactate and ATP
levels in HeLa cells. Fru-2,6-P2, lactate, and ATP were determined
enzymatically 72 h after treatment and the results were normalized to
protein concentration and expressed as fold change versus control.
Data are means ± S.E.M. from at least three experiments. Diﬀerences
P < 0.05 (*) were considered signiﬁcant. Abbreviations: c, Oligofecta-
mine control; c(), negative control; u, uPKF-2.
Fig. 3. Eﬀect of uPFK-2 silencing on HeLa cells growth. Cell number
was assayed over time by staining of cells with crystal violet and
measure of its absorbance at 550 nm. Upper graph (A) represents the
growth curves plotted from a representative experiment. Error bars
stand for intraexperimental replicates standard deviation. (B) Slope of
growth curves was deﬁned as growth rate and expressed as fold change
versus control. Average of four experiments is shown. Diﬀerences
P < 0.05 (*) and 0.01 (**) were considered signiﬁcant. Abbreviations:
c, Oligofectamine control; c(–) negative control; u, uPFK-2.
Fig. 4. Eﬀect of uPFK-2 silencing on HeLa cells apoptosis. Apoptosis
was assessed 72 h after treatment by staining cells with annexin V-FITC
and PI and subsequent FACS analysis of their ﬂuorescence, with cells
annexin V-/PI- considered as viable cells, cells annexin V+/PI- consid-
ered as early apoptotic cells and cells annexin V+/PI+ considered as late
apoptotic or necrotic cells. Histogram plots the average distribution in
the three states versus control from four experiments. Diﬀerences
P < 0.01 (**) and 0.001 (***) were considered signiﬁcant. Abbrevia-
tions: c, Oligofectamine control; c(–) negative control; u, uPFK-2.
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similarly to the results shown in Fig. 2.
An increase in Fru-2,6-P2 has an important role on the acti-
vation of glycolytic ﬂux in proliferating cells [34]. Therefore,
we evaluated the eﬀect of u-siRNA on the proliferation rate
of transfected HeLa cells harvested 24, 48, or 72 h after plat-
ing. Anchorage-dependent growth was assessed by counting
the number of cells in the culture dishes, which were measured
by the crystal violet assay and plotted versus time. A represen-
tative growth curve is shown in Fig. 3A. Cells treated with u-
siRNA exhibited a 20% reduction in the proliferation rate
compared to control (Fig. 3B). Recent in vitro and in vivo
experiments using speciﬁc inhibitors of PFK-2 [35] or blocking
glycolysis directly with the non-metabolizable glucose-
analogue 2-deoxy-glucose (2-DG) [36] have underlined the
relationship between glycolysis inhibition and cell damage
and survival.
The mechanism responsible for the antiproliferative eﬀect of
the u-siRNA was assessed, ﬁrstly, by cell staining with annexin
V-FITC and PI. A 40–50% decrease in cell viability (annexin
V-negative/PI-negative) was observed 48 h after transfection
(Fig. 4) and corroborated by staining with PI and FDA (ﬂuo-
rescein di-O-acetate) (data not shown). According to Vander
Heiden [37], stress-induced cell death is proportional to the
change on the glycolytic rate resulting from growth factors
or glucose depletion. Indeed, the mitogenic response of growth
factors is concomitant with the modulation they exert on PFK-
2 expression and it has thus been suggested that Fru-2,6-P2
intracellular levels could determine the glycolytic rate of prolif-
erating cells by coupling hormonal signals with the metabolic
demand [10]. The same cell staining technique let us explore
whether the decrease in the percentage of viable cells was re-
lated to an apoptotic process. As illustrated in Fig. 4, more
than 22% of HeLa cells transfected with u-siRNA were early
apoptotic (annexin V-positive/PI-negative). These results are
consistent with similar experiments carried out with the glu-
cose analogue 2-deoxy-glucose (2-DG) [38]. In contrast, cells
that overexpressed fructose-2,6-bisphosphatase and thus had
a low content of Fru-2,6-P2 showed a diminished tendency
to undergo both spontaneous and induced apoptosis, although
their ATP levels were 20% lower than control cells [39]. Thisdiﬀerence with our results may arise, ﬁrst, from the fact that
the stable transfection performed by Boada et al. may promote
the adaptation to a prolonged Fru-2,6-P2 decrease – unlike the
acute eﬀect of uPFK-2 silencing on HeLa cells. Secondly, the
cell line they used was Mv1Lu, a non-tumor epithelial cell line.
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glucose to lactate, which is independent of oxygen availability
and is assumed to entail a growth advantage for tumor expan-
sion [4,10]. Nevertheless, the shift from oxidative energy
metabolism to glycolysis leads tumor cells to depend on extra-
cellular glucose to maintain their ATP levels. In the case of
HeLa cells, a decrease in ATP levels results in an apoptosis in-
crease [40], which is consistent with our data (Fig. 2).
The eﬀect of u-siRNA on cell death could account for the
antiproliferative consequences seen so far. However, an eﬀect
on the cell cycle could also contribute to that result. Indeed,
when quiescent cells are stimulated to proliferate, the expres-
sion of several genes is induced at the G1/S transition. These
genes code for proteins involved in cell-cycle progression, for
enzymes of DNA synthesis and, as it has previously been
shown, for PFK-2 [41]. To check whether silencing of uPFK-
2 aﬀected the cell cycle, HeLa cells were synchronized in G0/
G1 by serum depletion for 48 h post-transfection. Subse-
quently, cells were challenged to re-enter the cell cycle for
12 h by adding 10% FBS medium. Finally, cells were ﬁxed
on ethanol, stained with PI and processed by FACS to estab-
lish the distribution of cells in the cell-cycle phases. Treatment
with u-siRNA decreased the ability of cells to progress from
G0/G1 to S, which resulted in an accumulation of cells in
G0/G1 (Fig. 5).
Finally we examined the eﬀects of uPFK-2 on anchorage-
independent growth, one of the hallmarks of transformation.
HeLa cells grow and form foci in a semisolid culture. This
capacity is not altered when cells are transfected with
100 nM negative control siRNA. However, treatment with
100 nM u-siRNA or co-siRNA (also positive control, 2.5 nM
paclitaxel) clearly abolished this ability (Fig. 6A). Quantiﬁca-Fig. 5. Eﬀect of uPFK-2 silencing on HeLa cells cycle. Cell cycle was
studied 72 h after treatment by staining DNA with PI and subsequent
FACS analysis. Cells were synchronized in G0/G1 by total FBS
depletion during 48 h and induced to re-enter the cell cycle by addition
of complete medium for 12 h. Histograms represent the distribution of
cells in G0/G1, S and G2/M. A representative experiment of three is
shown. Abbreviations: c, Oligofectamine control; c(–) negative control;
u, uPFK-2.
Fig. 6. Eﬀect of uPFK-2 silencing on anchorage-independent growth
of HeLa cells. (A) Representative pictures of soft agar colonies formed
by HeLa cells grown for 10 days (40·). (B) Bars represent fold change
versus control from at least three independent experiments. Diﬀerences
P < 0.001 (***) were considered signiﬁcant. Abbreviations: c, Oligo-
fectamine control; c()siRNA1 and c()siRNA2, negative control
siRNAs; paclitaxel (2,5 nM for 24 h), positive control; u, uPFK-2, and,
co-siRNA, common siRNA against all pfkfb3 mRNAs.tion as fold change versus control of the mean colony counts
of three independent experiments is summarized in Fig. 6B.
Despite the relatively modest eﬀects obtained at the meta-
bolic level, the siRNA against uPFK-2 decreased cell prolifer-
ation and greatly inhibited anchorage-independent growth,
suggesting that the substantial decrease of uPFK-2 (Fig. 1B)
could have additional non-glycolytic consequences. In this re-
gard, it has been shown that the heart PFK-2 isoenzyme and
the isoenzyme from Arabidopsis thaliana bind 14-3-3 proteins
[42], which have been implicated in promoting cell survival
[43]. At present, there are no studies with other isoenzymes
in this ﬁeld. Numerous studies, reviewed in [44], are providing
intriguing evidence of the unexpected nature of glycolytic
enzymes but current understanding of the functions of these
M.N. Calvo et al. / FEBS Letters 580 (2006) 3308–3314 3313enzymes beyond glycolysis is still insuﬃcient and will surely ex-
pand in the near future. In this sense, it is interesting that most
glycolytic enzymes that display non-glycolytic functions con-
tain evolutionarily conserved consensus Myc-binding sites or
E-boxes among their regulatory DNA sequences [45] and these
sequences are also present in pfkfb3 gene [18]. Work is in pro-
gress to elucidate other roles this gene may have.
In conclusion, uPFK-2 has a relevant implication in the rela-
tionship between glycolysis, cell proliferation and transforma-
tion. This isoenzyme is one of the metabolic eﬀectors that
facilitates the adaptation and survival of proliferating and tu-
mor cells in their hypoxic microenvironment. Suppression of
glycolysis may be an eﬀective alternative to traditional cancer
therapies and, accordingly, the inhibition of pfkfb3 expression
could be one of the targets of such an approach.
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